OCIAML5_HAEMATOPOIETIC_AND_LYMPHOID_TISSUE
AML · Acute Myeloid Leukemia
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- AML
- cancer_type_detailed
- Acute Myeloid Leukemia
- subtype
- —
- cancer_type
- AML
- ccle_sample_id
- OCIAML5_HAEMATOPOIETIC_AND_LYMPHOID_TISSUE
- synthetic_from_ccle
- true
- display_name
- OCI-AML5
- ccle_lineage
- blood
- ccle_lineage_subtype
- AML
- oncotree_code
- AML
- cancer_type_detailed
- Acute Myeloid Leukemia
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ALLOGRAFT_REJECTION+0.603
- INFLAMMATORY_RESPONSE+0.373
- IL6_JAK_STAT3_SIGNALING+0.257
- INTERFERON_GAMMA_RESPONSE+0.257
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.211
- MYC_TARGETS_V2+0.195
- MYC_TARGETS_V1+0.131
- INTERFERON_ALPHA_RESPONSE+0.119
- IL2_STAT5_SIGNALING+0.092
- COMPLEMENT+0.080
Top 10 suppressed
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.533
- PROTEIN_SECRETION-0.467
- TGF_BETA_SIGNALING-0.439
- HEDGEHOG_SIGNALING-0.326
- NOTCH_SIGNALING-0.308
- GLYCOLYSIS-0.303
- COAGULATION-0.290
- UV_RESPONSE_DN-0.256
- XENOBIOTIC_METABOLISM-0.231
- APICAL_SURFACE-0.225
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | OCIAML2_HAEMATOPOIETIC_AND_LYMPHOID_TISSUE | AML | — | 0.888 |
| 2 | EOL1_HAEMATOPOIETIC_AND_LYMPHOID_TISSUE | AML | — | 0.859 |
| 3 | KO52_HAEMATOPOIETIC_AND_LYMPHOID_TISSUE | AML | — | 0.848 |
| 4 | NOMO1_HAEMATOPOIETIC_AND_LYMPHOID_TISSUE | AML | — | 0.839 |
| 5 | KASUMI6_HAEMATOPOIETIC_AND_LYMPHOID_TISSUE | AML | — | 0.836 |
| 6 | MOLM6_HAEMATOPOIETIC_AND_LYMPHOID_TISSUE | CML | — | 0.802 |
| 7 | TCGA-CR-6487-01A-11R-1873-07 | — | — | 0.772 |
| 8 | SRR25617828 | — | D | 0.772 |
| 9 | TCGA-E2-A1B6-01A-31R-A12P-07 | — | D | 0.771 |
| 10 | SRR8518222 | — | D | 0.767 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 18 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ALLOGRAFT_REJECTION | 0.603 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.373 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.257 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.257 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.211 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.195 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.131 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.119 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.092 | Idelalisib | — uncovered |
| COMPLEMENT | 0.080 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.050 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.044 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.040 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.020 | Remibrutinib | — uncovered |
| E2F_TARGETS | 0.016 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.012 | Idelalisib | — uncovered |
| ADIPOGENESIS | 0.010 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.005 | Inavolisib | — uncovered |